MA31881B1 - Dérivés de n-(arylamino)arylsulfonamide comprenant des polymorphes en tant qu'inhibiteurs de mek ainsi que compositions, procédés d'utilisation et procédés de préparation de ceux-ci - Google Patents

Dérivés de n-(arylamino)arylsulfonamide comprenant des polymorphes en tant qu'inhibiteurs de mek ainsi que compositions, procédés d'utilisation et procédés de préparation de ceux-ci

Info

Publication number
MA31881B1
MA31881B1 MA32636A MA32636A MA31881B1 MA 31881 B1 MA31881 B1 MA 31881B1 MA 32636 A MA32636 A MA 32636A MA 32636 A MA32636 A MA 32636A MA 31881 B1 MA31881 B1 MA 31881B1
Authority
MA
Morocco
Prior art keywords
methods
compositions
compounds
mek inhibitors
arylsifonamide
Prior art date
Application number
MA32636A
Other languages
Arabic (ar)
English (en)
Inventor
Jean-Michel Vernier
Colin Edward Rowlings
Jean-Luc Girardet
Barry Quart
Jeffrey N Miner
Stuart Dimock
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40304796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31881(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/830,733 external-priority patent/US8101799B2/en
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of MA31881B1 publication Critical patent/MA31881B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N41/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom
    • A01N41/02—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom containing a sulfur-to-oxygen double bond
    • A01N41/04—Sulfonic acids; Derivatives thereof
    • A01N41/06—Sulfonic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Vascular Medicine (AREA)
  • Dentistry (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)

Abstract

L'invention concerne des composés n-(arylamino)arylsulfonamide qui sont des inhibiteurs de mek comprenant des formes polymorphes cristallines présentant un profil de diffraction aux rayons x sur poudre spécifique et/ou un profil de calorimétrie à balayage différentiel spécifique. La présente invention concerne également des compositions pharmaceutiques comprenant les composés et des procédés d'utilisation des composés et des compositions décrits ici, y compris l'utilisation dans le traitement et/ou la prévention du cancer, de maladies hyperprolifératives et d'affections inflammatoires. L'invention concerne également des procédés de préparation des composés et des compositions décrits ici.
MA32636A 2007-07-30 2010-02-19 Dérivés de n-(arylamino)arylsulfonamide comprenant des polymorphes en tant qu'inhibiteurs de mek ainsi que compositions, procédés d'utilisation et procédés de préparation de ceux-ci MA31881B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11/830,733 US8101799B2 (en) 2005-07-21 2007-07-30 Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US3446408P 2008-03-06 2008-03-06
US3446608P 2008-03-06 2008-03-06
US4488608P 2008-04-14 2008-04-14
PCT/US2008/071392 WO2009018233A1 (fr) 2007-07-30 2008-07-28 Dérivés de n-(arylamino)arylsulfonamide comprenant des polymorphes en tant qu'inhibiteurs de mek ainsi que compositions, procédés d'utilisation et procédés de préparation de ceux-ci

Publications (1)

Publication Number Publication Date
MA31881B1 true MA31881B1 (fr) 2010-12-01

Family

ID=40304796

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32636A MA31881B1 (fr) 2007-07-30 2010-02-19 Dérivés de n-(arylamino)arylsulfonamide comprenant des polymorphes en tant qu'inhibiteurs de mek ainsi que compositions, procédés d'utilisation et procédés de préparation de ceux-ci

Country Status (23)

Country Link
EP (1) EP2184984A4 (fr)
JP (3) JP2010535232A (fr)
KR (3) KR20100092424A (fr)
CN (2) CN103479604B (fr)
AP (1) AP2817A (fr)
AU (2) AU2008282338B2 (fr)
BR (1) BRPI0815659A2 (fr)
CA (1) CA2693390C (fr)
CO (1) CO6470808A2 (fr)
CR (1) CR11244A (fr)
DO (1) DOP2010000045A (fr)
EA (2) EA032294B1 (fr)
EC (1) ECSP109910A (fr)
HK (1) HK1147396A1 (fr)
HN (1) HN2010000203A (fr)
IL (1) IL203296A (fr)
MA (1) MA31881B1 (fr)
MX (1) MX2010001244A (fr)
NZ (1) NZ582929A (fr)
PH (1) PH12015501914A1 (fr)
SV (1) SV2010003469A (fr)
TN (1) TN2010000049A1 (fr)
WO (1) WO2009018233A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
CN102131771A (zh) * 2008-04-14 2011-07-20 阿迪生物科学公司 组合物及其制备和使用方法
KR20180001582A (ko) * 2008-09-09 2018-01-04 에프. 호프만-라 로슈 아게 아실 설폰아미드의 다형체
MX2011003183A (es) 2008-09-26 2011-04-21 Oncomed Pharm Inc Agentes que se unen a receptor encrespado y usos de los mismos.
UY32486A (es) * 2009-03-11 2010-10-29 Ardea Biosciences Inc Tratamiento del cáncer de páncreas
MX2011009498A (es) * 2009-03-11 2011-10-14 Ardea Biosciences Inc Combinaciones farmaceuticas que comprenden rdea119/bay 869766 para el tratamiento de canceres especificos.
ES2534358T3 (es) 2009-10-13 2015-04-21 Allomek Therapeutics, Llc Inhibidores novedosos de MEK útiles en el tratamiento de enfermedades
EP2491015A1 (fr) * 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Benzosulfonamides substitués
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
CN102649773A (zh) * 2011-02-23 2012-08-29 苏州波锐生物医药科技有限公司 氨基芳香烃类化合物及其在制备抗恶性肿瘤药物中的用途
KR102196424B1 (ko) * 2011-04-28 2020-12-30 슬로안-케테링인스티튜트퍼캔서리서치 Hsp90 병용요법
AR086553A1 (es) * 2011-05-27 2014-01-08 Bayer Ip Gmbh Sintesis quiral de n-{3,4-difluoro-2-[(2-fluoro-4-yodofenil)amino]-6-metoxifenil}-1-[2,3-dihidroxi-propil]ciclopropano sulfonamidas
US20150132301A1 (en) * 2011-12-09 2015-05-14 Oncomed Pharmaceuticals, Inc. Combination Therapy for Treatment of Cancer
WO2013109142A1 (fr) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Inhibition de la voie des mapk/erk et pdk combinée dans des cas de néoplasie
AU2013269809B2 (en) * 2012-05-31 2017-12-21 Bayer Pharma Aktiengesellschaft Biomarkers for determining effective response of treatments of Hepatocellular carcinoma (HCC) patients
KR20190040370A (ko) 2012-06-04 2019-04-17 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
HRP20240033T1 (hr) * 2012-10-19 2024-03-29 Array Biopharma, Inc. Formulacija koja sadrži inhibitor mek
CA2890238A1 (fr) 2012-11-02 2014-05-08 Merck Patent Gmbh Methode de reduction des effets secondaires chez un patient souffrant de cancer traite par un inhibiteur de la mek
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
EP2848246A1 (fr) 2013-09-13 2015-03-18 Bayer Pharma Aktiengesellschaft Compositions pharmaceutiques contenant du refametinib
WO2015041534A1 (fr) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk en combinaison avec raf/erk/mek
US9629851B2 (en) 2013-09-20 2017-04-25 Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis ROCK in combination with MAPK pathway
WO2015156674A2 (fr) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Méthode de traitement du cancer
WO2015178770A1 (fr) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions pour le traitement du cancer
US20160051639A1 (en) * 2014-08-25 2016-02-25 Aimmune Therapeutics, Inc. Egg protein formulations and methods of manufacture thereof
CN107427498A (zh) 2015-03-03 2017-12-01 药品循环有限责任公司 布鲁顿氏酪氨酸激酶抑制剂的医药配方
EP3638241B1 (fr) * 2017-06-16 2022-05-25 Beta Pharma, Inc. Formulations pharmaceutiques de n-(2-(2-(diméthylamino)éthoxy)-4-méthoxy-5-((4-(1-méthyl-1h-indole-3-yl)pyrimidine-2-yl)amino)phényl)acrylamide et de sels de ce dernier
EP3942045A1 (fr) 2019-03-21 2022-01-26 Onxeo Molécule dbait associée à un inhibiteur de kinase pour le traitement du cancer
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
JP2575590B2 (ja) * 1992-07-31 1997-01-29 塩野義製薬株式会社 トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法
ES2123065T3 (es) * 1992-08-25 1999-01-01 Searle & Co Hidroxietilamino-sulfonamidas utiles como inhibidores de proteasas retroviricas.
US7115632B1 (en) * 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
AP2001002225A0 (en) * 1999-01-13 2001-09-30 Warner Lambert Co 1-heterocycle substituted diarylamines.
GB0003224D0 (en) * 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
IL161036A0 (en) * 2001-09-24 2004-08-31 Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
KR20050040907A (ko) * 2002-07-17 2005-05-03 타이탄 파머슈티컬즈 인코퍼레이티드 항종양 활성 증강용 화학요법제의 조합
DK1545553T3 (da) * 2002-07-30 2011-09-12 Aeterna Zentaris Gmbh Anvendelse af alkylphosphocholiner i kombination med antitumormedikamenter
WO2006110811A1 (fr) * 2005-04-12 2006-10-19 Elan Pharma International Limited Formules de nanoparticules de derives de quinazoline
EP1876167A4 (fr) * 2005-04-22 2010-07-07 Kissei Pharmaceutical Polymorphisme cristallin d'hydrochlorure d'acide 4 -{2-ý(1s,2r)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethylamino¨ethoxy}-3-isopropyl-3 ,5 -dimethylbiphenylcarboxylique
PT1912636E (pt) * 2005-07-21 2014-07-24 Ardea Biosciences Inc Inibidores de n-(arilamino)-sulfonamida de mek
JP2007099763A (ja) * 2005-09-08 2007-04-19 Toyama Chem Co Ltd ピペラシリンナトリウム・１水和物の新規な結晶及びその製造方法
TW200800150A (en) * 2005-12-21 2008-01-01 Organon Nv Compounds with medicinal effects due to interaction with the glucocorticoid receptor

Also Published As

Publication number Publication date
EA032294B1 (ru) 2019-05-31
EP2184984A4 (fr) 2013-07-24
MX2010001244A (es) 2010-08-31
AP2010005134A0 (en) 2010-02-28
CN103479604B (zh) 2016-08-10
CA2693390C (fr) 2017-01-17
CA2693390A1 (fr) 2009-02-05
CN103479604A (zh) 2014-01-01
EP2184984A1 (fr) 2010-05-19
KR20140098185A (ko) 2014-08-07
HK1147396A1 (en) 2011-08-12
WO2009018233A1 (fr) 2009-02-05
DOP2010000045A (es) 2010-10-31
JP2015078199A (ja) 2015-04-23
NZ582929A (en) 2012-03-30
KR20100092424A (ko) 2010-08-20
ECSP109910A (es) 2010-04-30
IL203296A (en) 2017-06-29
SV2010003469A (es) 2010-04-30
CN101808516A (zh) 2010-08-18
EA201400552A1 (ru) 2014-09-30
JP2010535232A (ja) 2010-11-18
JP2017125021A (ja) 2017-07-20
AU2008282338A1 (en) 2009-02-05
EA201000268A1 (ru) 2010-08-30
KR20150091434A (ko) 2015-08-10
TN2010000049A1 (en) 2011-09-26
AP2817A (en) 2013-12-31
CN101808516B (zh) 2013-08-28
CR11244A (es) 2010-05-20
CO6470808A2 (es) 2012-06-29
AU2015200390B2 (en) 2017-02-23
PH12015501914A1 (en) 2017-07-31
AU2008282338B2 (en) 2015-02-12
JP6309880B2 (ja) 2018-04-11
BRPI0815659A2 (pt) 2014-09-30
EA020624B1 (ru) 2014-12-30
HN2010000203A (es) 2012-11-19

Similar Documents

Publication Publication Date Title
MA31881B1 (fr) Dérivés de n-(arylamino)arylsulfonamide comprenant des polymorphes en tant qu'inhibiteurs de mek ainsi que compositions, procédés d'utilisation et procédés de préparation de ceux-ci
TNSN05298A1 (fr) Derives de pyrazolo-quinazoline, procede pour leur preparation et leur utilisation comme inhibiteurs de kinases
TNSN08099A1 (fr) 1-h-imidazopyridines a substituant hydroxy et procedes
MA30967B1 (fr) Sels et formes cristallines de 2-methyl-2-methyl-2-[4-(3-methyl-2-oxo-8-quinolein-3-yl-2,3-dihydro-imidazo[4,5-c]quinolein-1-yl) - phenyl]-propionitrile.
MA29713B1 (fr) Derives de tetrahydroindolone et de tetrahydroindazolone
WO2006053121A3 (fr) Certaines imidazo[1,2-a] pyrazin-8-ylamines et les procédés de fabrication et d'utilisation correspondants
WO2009039397A3 (fr) Amides substitués, procédé pour les préparer et procédé pour les utiliser
MA30089B1 (fr) (arylsulfonyl)-pyrasolopiperidines
MA33502B1 (fr) Composés pyrazolopyrimidine inhibiteurs des jak et procédés
TW200716551A (en) Certain substituted amides, method of making, and method of use thereof
TNSN07476A1 (fr) Derives de n-(pyridine -2- yl) - sulfonamide
WO2008033857A3 (fr) Amides substitués, procédé de production et d'utilisation desdits amides
BRPI0513843A (pt) composto ou um sal ou solvato ou uma pró-droga farmaceuticamente aceitável do mesmo, composição farmacêutica, forma de dosagem, uso de um composto, e, sal de cloridrato
UA86970C2 (en) Morpholine compounds
MA32627B1 (fr) Derive d'amides heteroaryliques et leur utilisation comme activateurs de glucokinase
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
DE60226729D1 (de) Hydroxyalkylaminderivate als beta-secretase-inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
TW200607807A (en) Macrocyclic beta-secretase inhibitors
MA32230B1 (fr) Formes cristallines et deux formes solvatées de lactates de 4-amino-5-fluoro -3-[5-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one
BR0313923A (pt) Derivados de 3-(sulfonamidoetil)-indol para uso como miméticos de glicocorticóide no tratamento de doenças inflamatórias, alérgicas e proliferativas
ATE482192T1 (de) Pyrrolidinderivate zur behandlung einer von der reninaktivität abhängigen krankheit
WO2005051914A8 (fr) Inhibiteurs de benzylether et benzylamino de beta-secretase pour traiter la maladie d'alzheimer
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA31857B1 (fr) N-phenyl-pyrrolidinylmethylpyrrolidine-amides substitues et utilisation therapeutique de ceux -ci